MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491

MyoKardia (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in a Phase 1b single-ascending dose patient study of its investigational drug candidate MYK-491.

As quoted in the press release:

“Patients with DCM suffer from debilitating symptoms due to inadequate cardiac contraction and the consequent insufficient blood flow characteristic of their disease.  There are currently no approved therapies that directly target the depressed contractility present in dilated cardiomyopathy,” said Marc Semigran, M.D., Chief Medical Officer of MyoKardia.  “MYK-491 was designed to address the underlying biomechanical cause of DCM.  As we advance into further clinical testing, we look forward to gaining insights into MYK-491’s potential to increase cardiac contractility and we are hopeful this drug candidate may restore the heart’s contractility towards normal function in patients.”

Click here to read the full press release.